Circulating Superoxide Dismutase Concentrations in Obstructive Sleep Apnoea (OSA): A Systematic Review and Meta-Analysis

Maria Carmina Pau 1,*, Arduino Aleksander Mangoni 2, Elisabetta Zinellu 3, Gianfranco Pintus 4,5, Ciriaco Carru 4,6, Alessandro Giuseppe Fois 1,3, Pietro Pirina 1,3 and Angelo Zinellu 4

Abstract: Obstructive Sleep Apnoea (OSA) is characterized by a pro-oxidant state that results from the recurrent hypoxia-reoxygenation cycles. Superoxide dismutase (SOD), a key antioxidant enzyme involved in the detoxification of superoxide radicals, could represent a reliable marker to monitor the antioxidant defences in OSA. In order to capture and critically appraise the available evidence, we performed a systematic review and meta-analysis of studies reporting SOD concentrations in OSA patients and non-OSA controls in the electronic databases Pubmed, Web of Science, Scopus and Google Scholar. In total, 13 studies in 847 OSA patients and 438 non-OSA controls were included in the meta-analysis. Blood SOD concentrations were significantly lower in OSA patients (SMD = 0.87, \(p < 0.001\)). By contrast, serum/plasma SOD concentrations were not significantly different between the two groups. Although extreme between-study heterogeneity was observed, the SMD was not substantially modified when individual studies were sequentially removed. In conclusion, we observed that whole blood, but not serum/plasma, SOD concentrations were significantly lower in OSA patients compared with controls. Our meta-analysis suggests an impaired antioxidant defence in OSA that is more robustly assessed in the corpuscular biological matrix and provides useful background information for further studies investigating the association between SOD changes and clinical status in OSA.

Keywords: obstructive sleep apnoea; oxidative stress; superoxide dismutase

1. Introduction

Obstructive Sleep Apnoea (OSA) is characterized by episodes of upper airway obstruction and intermittent cycles of desaturation–reoxygenation [1]. In particular, the reoxygenation phase is considered to promote oxidative stress with excessive ROS production, reduced activity of antioxidant defences, or a combination of both [2,3]. Whilst OSA represents an independent risk factor for cardiovascular disease, the exact mechanisms involved in this association are not fully understood [4,5]. The imbalance between ROS production and antioxidant capacity might account, at least in part, for the link between OSA and cardiovascular disease [6,7]. Under conditions of oxidative stress, the superoxide radical, generated principally during mitochondrial respiration, represents the most
abundant ROS [8]. This key agent is capable of oxidizing a variety of cellular components including lipids, proteins and DNA, with consequent alteration of their biological functions [9]. The antioxidant system, constituted by different molecules and enzymes, represents a critical defence against radicals-related damage. Superoxide dismutase (SOD) is a metallic enzyme that allows the dismutation of the superoxide anion into molecular oxygen and hydrogen peroxide [8,10]. Among the antioxidant defence mechanisms, SOD is primarily involved in the process of detoxification of superoxide radicals. Thus, a decrease in the circulating concentrations of this enzyme would reflect an impaired antioxidant defence (Figure 1). Several studies have investigated the role of oxidative stress markers, including indicators of lipid peroxidation, protein carbonylation and DNA oxidation, as well as the activity of the antioxidant enzymes SOD and glutathione peroxidase, in OSA [11–13]. While these studies generally reported correlations between some of these markers and the presence and severity of OSA, conflicting results exist regarding SOD concentrations in this group [14]. Furthermore, CPAP therapy, a fundamental treatment strategy in OSA also in view of its antioxidant effects, have shown to have little effect on SOD concentrations, in contrast to oxidative stress markers such as 8-isoprostane and 8-hydroxy-2-deoxyguanosine [15]. Therefore, in order to capture and critically appraise the available evidence on the pathophysiological role of SOD, we performed a systematic review and meta-analysis of studies reporting SOD concentrations in serum, plasma, and whole blood in OSA patients and non-OSA controls to detect possible differences between the two groups.

Figure 1. Flow chart describing the role of antioxidant defence molecules in the pathogenesis of OSA. GSH: glutathione; SOD: superoxide dismutase.

2. Materials and Methods
2.1. Search Strategy, Eligibility Criteria, and Study Selection

We conducted a systematic search of publications in the electronic databases Pubmed, Web of Science, Scopus and Google Scholar, from inception to June 2021, using the following terms and their combination: “superoxide dismutase” or “SOD” and “Obstructive Sleep Apnoea Syndrome” or “OSAS” or “OSA” or “OSAHS” (PROSPERO registration number: CRD42021272833).
In order to establish relevance, the abstracts were screened independently by two investigators. If relevant, the two investigators independently reviewed the full articles. The references of the retrieved articles were also searched to identify additional studies. A third investigator was involved in presence of any disagreement between the reviewers. The eligibility criteria were: (i) evaluation of SOD concentrations in blood, plasma or serum/plasma; (ii) comparison between subjects with OSA and non-OSA (case–control design); (iii) studies reporting apnoea–hypopnea index (AHI) values; (iv) studies in adult patients; (v) sample size ≥10 OSA patients; (vi) English language and (vii) availability of full-text publications. Risk of bias was evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for analytical cross-sectional studies, with scores ≥5, 4, and <4 indicating low, moderate, and high risk, respectively [16]. Certainty of evidence was assessed using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) Working Group system, which considers the study design (randomized vs. observational), risk of bias (JBI checklist), presence of unexplained heterogeneity, indirectness of evidence, imprecision of results (sample size, 95% confidence interval width and threshold crossing), effect size (small, SMD < 0.5, medium, SMD 0.5–0.8, and large, SMD > 0.8), and high probability of publication bias.

2.2. Statistical Analysis

Considering that the SOD concentrations were expressed using different units of measurement (U/L, U/gHb, ng/mL or %), the forest plots of continuous data and the assessment of the differences in SOD concentrations in OSA patients vs. non-OSA were expressed using the standardized mean differences (SMDs). The presence of \( p < 0.05 \) was considered statistically significant, and 95% confidence intervals (CIs) were reported. When required, the values of mean and standard deviation were extrapolated from median and IQR values, or from median and range as previously reported by Wan et al. [17] as described by Hozo et al. [18] or from graphs using the Graph Data Extractor software. The Q statistic was used to test heterogeneity of SMD across studies (significance level at \( p < 0.10 \)). Additionally, the I2 statistic, a quantitative measure of inconsistency between studies, was calculated (I2 < 25%, no heterogeneity; I2 between 25% and 50%, moderate heterogeneity; I2 between 50% and 75%, large heterogeneity; and I2 > 75%, extreme heterogeneity) [19,20]. Statistical heterogeneity was established in the presence of an I2 statistic value ≥50% [20]. When the analyses detected high heterogeneity, a random-effects model was applied. Sensitivity analysis was also performed to test the influence of any single study on the overall risk estimate by excluding each study sequentially [21]. For each effect size the confidence intervals at 95% (CIs) and the overall effect were reported, and \( p < 0.05 \) was considered statistically significant. The study was compliant with the principles outlined in the PRISMA 2020 Statement [22] concerning the reporting of systematic reviews and meta-analyses. The software Stata 14 was used to perform statistical (STATA Corp., College Station, TX, USA).

3. Results

3.1. Systematic Research

A flow chart describing the screening process is presented in Figure 2. We initially identified 1449 studies. A total of 1433 studies were excluded after the first screening because they were either duplicates or irrelevant. After a full-text revision of 16 articles, three studies were further excluded because of missing information. Thus, thirteen studies were included in the meta-analysis [14,23–34]. A total of 847 OSA patients (mean age 47 years, 74% males) and 438 controls (mean age 50 years, 72% males) were evaluated. The characteristics of the retrieved studies, published between 2005 and 2020, are presented in Table 1.
74% males) and 438 controls (mean age 50 years, 72% males) were evaluated. The characteristics of the retrieved studies, published between 2005 and 2020, are presented in Table 1.

**Figure 2.** Flow chart of study selection.

**Table 1.** Summary of the studies on controls vs. OSA subjects included in the meta-analysis.

| First Author Year, Country | Control | OSA | AHI Events/h |
|----------------------------|---------|-----|--------------|
|                            | n       | Age Mean | Gender (M/F) | SOD Mean ± SD | n       | Age Mean | Gender (M/F) | SOD Mean ± SD |               |
|---------------------------|---------|-----------|--------------|---------------|---------|-----------|--------------|---------------|---------------|
| **BLOOD**                 |         |           |              |               |         |           |              |               |               |
| Alzoghaibi MA et al., 2005, Saudi Arabia | 17      | 50        | NR           | 0.31 ± 0.04 U/L | 25      | 31        | NR           | 0.29 ± 0.08 U/L | 73.5          |
| Cofta S et al., 2008, Poland | 21      | 53        | 11/10        | 1579 ± 325 U/gHb | 61      | 52        | 43/18       | 1096 ± 295 U/gHb | 24            |
| Yagihara F et al., 2012, Brasil | 27      | 66        | 27/0         | 10.2 ± 4.0 U/mgHb | 30      | 66        | 30/0        | 10.5 ± 2.9 U/mgHb | 38            |
| Ntalapascha M et al., 2013, Greece | 13      | 49        | 13/0         | 195 ± 39 ng/mL | 18      | 50        | 18/0        | 191 ± 33 ng/mL | 24            |
| Sales LV et al., 2013, Brasil | 13      | 37        | 13/0         | 14.4 ± 2.3 U/mgHb | 14      | 36        | 14/0        | 10.0 ± 2.9 U/mgHb | 36            |
| Wysocka E et al., 2013, Poland | 44      | 55        | 44/0         | 1408 ± 181 U/gHb | 44      | 53        | 44/0        | 1217 ± 234 U/gHb | 26            |
| Chen P et al., 2013, Taiwan | 20      | 42        | 15/5         | 3.60 ± 0.81 U/mgHb | 44      | 42        | 33/11       | 2.37 ± 1.24 U/mgHb | 15            |
| El-Kholy MG et al., 2015, Egypt | 20      | 49        | 10/10        | 117 ± 25 U/mL | 20      | 51        | 9/11        | 83 ± 19 U/mL | 30            |
| **SERUM/PLASMA**          |         |           |              |               |         |           |              |               |               |
| Murri ET et al., 2010, Spain | 15      | 54        | 15/0         | 0.070 ± 0.029 U/mL | 28      | 46        | NR          | 0.062 ± 0.026 U/mL | 52            |
| Lee SD et al., 2012, South Korea | 20      | 44        | 20/0         | 1.34 ± 0.66 U/mL | 53      | 47        | 53/0        | 1.21 ± 0.66 U/mL | 32            |
| Yildirim T et al., 2017, Turkey | 129     | 49        | 78/51        | 13.6 ± 1.5 NR | 131     | 49        | 74/57       | 8.9 ± 1.4 NR | 34            |
| Zhou L et al., 2018, China | 28      | 45        | 20/8         | 316 ± 103 ng/mL | 48      | 41        | NR          | 116 ± 132 ng/mL | 47            |
| Peres BU et al., 2020, Canada | 71      | 52        | 38/33        | 19.74 ± 10.05 % | 331     | 45        | 237/94      | 18.00 ± 9.30 % | 26            |

AHI: apnoea–hypopnea index; SOD: superoxide dismutase; NR = Not reported.
3.2. Meta-Analysis of Blood SOD Concentrations

3.2.1. Study Characteristics

Eight studies with a total of 256 OSA patients (mean age 49 years, 82% males), and 175 controls (mean age 52 years, 84% males) were evaluated [23–30].

3.2.2. Risk of Bias

The risk of bias was considered low in seven studies [24–30] and moderate in the remaining one [23] (Table 2).

Table 2. The Joanna Briggs Institute critical appraisal checklist for analytical cross-sectional studies.

| Study         | Were the Criteria for Inclusion in the Sample Clearly Defined? | Were the Study Subjects and the Setting Described in Detail? | Was the Exposure Measured in a Valid and Reliable Way? | Were Objective, Standard Criteria Used for Measurement of the Condition? | Were Confounding Factors Identified? | Were Strategies to Deal with Confounding Factors Stated? | Were the Outcomes Measured in a Valid and Reliable Way? | Was Appropriate Statistical Analysis Used? | Risk of Bias |
|---------------|-----------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------|------------------------------------------------------|--------------------------------------------------|------------------------------------------|-------------|
| Alzoghaibi    | Unclear                                                         | Yes                                                       | Yes                                                  | No                                                                    | No                                 | Yes                                                  | No                                               | No                                                      | Moderate    |
| Cofta         | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | No                                 | No                                                   | Yes                                              | No                                                      | Low         |
| Yagihara      | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | No                                 | Yes                                                  | No                                               | No                                                      | Low         |
| Nptalapascha  | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | Yes                                | Yes                                                  | Yes                                              | Yes                                                     | Low         |
| Sales         | Yes                                                             | Yes                                                       | Yes                                                  | No                                                                    | No                                 | Yes                                                  | No                                               | No                                                      | Low         |
| Wysocka       | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | No                                 | Yes                                                  | No                                               | No                                                      | Low         |
| Chen          | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | No                                 | Yes                                                  | No                                               | No                                                      | Low         |
| El-Kholy      | Yes                                                             | Yes                                                       | Yes                                                  | No                                                                    | No                                 | Yes                                                  | No                                               | No                                                      | Low         |
| Murri         | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | No                                 | Yes                                                  | No                                               | No                                                      | Low         |
| Lee           | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | Yes                                | Yes                                                  | Yes                                              | Yes                                                     | Low         |
| Yildirim      | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | No                                 | Yes                                                  | No                                               | No                                                      | Low         |
| Zhou          | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | Yes                                | Yes                                                  | Yes                                              | Yes                                                     | Low         |
| Peres         | Yes                                                             | Yes                                                       | Yes                                                  | Yes                                                                   | Yes                                | Yes                                                  | Yes                                              | Yes                                                     | Low         |

3.2.3. Results of Individual Studies and Syntheses

The forest plot for blood SOD concentrations in OSA patients and controls in the eight studies is reported in Figure 3. In seven studies [23,24,26–30], OSA patients had lower blood SOD concentrations compared to controls (mean difference range, −1.67 to −0.11) and the difference was statistically significant in five [24,27–30]. Extreme heterogeneity between studies was observed ($I^2 = 79.4\%$, $p < 0.001$). Thus, random-effects models were used. Overall, pooled results showed that blood SOD concentrations were significantly lower in patients with OSA (SMD = −0.87, 95% CI −1.34 to −0.40; $p < 0.001$). Sensitivity analysis showed that the corresponding pooled SMD values were not substantially altered when any single study was in turn omitted (effect size range, between −0.97 and −0.76, Figure 4).

3.2.4. Publication Bias

Assessment of publication bias was not possible because of the relatively small number of studies.

3.2.5. Certainty of Evidence

The initial level of certainty for blood SOD SMD values was considered low because of the observational nature of the selected studies (rating 2, ⊗⊗⊗⊗). After considering the presence of a low risk of bias in seven out of eight studies (no rating change required), a generally extreme and unexplained heterogeneity (serious limitation, downgrade one level), lack of indirectness (no rating change required), the relatively low imprecision
(relatively narrow confidence intervals without threshold crossing, upgrade one level), the relatively large effect size (SMD $-0.87$, upgrade one level), and lack of assessment of publication bias (downgrade one level), the overall level of certainty was considered low (rating 2, ⊕⊕⊖⊖).

### Table 1: Meta-Analysis of Serum/Plasma SOD Concentrations

| Study                | Year | SMD (95% CI) | OSA, mean (SD) | CTRL, mean (SD) | % |
|----------------------|------|--------------|----------------|------------------|----|
| Azoghiabi VA et al.  | 2005 | -0.32 (-0.94, 0.30) | 25, 29 (0.75) | 17, 31 (0.4) | 12.56 |
| Cofta S et al.       | 2009 | -1.69 (-2.15, -1.04) | 61, 1069 (235) | 21, 1579 (325) | 13.14 |
| Yaghara F et al.     | 2012 | 0.09 (-0.43, 0.61) | 30, 105 (2.3) | 27, 102 (4) | 13.43 |
| Nikapanscha M et al. | 2013 | -0.11 (-0.63, 0.60) | 18, 191 (33) | 13, 106 (39) | 11.72 |
| Sales LV et al.      | 2013 | -1.67 (-2.56, -0.79) | 14, 10 (2.9) | 13, 14 (2.3) | 10.22 |
| Wysoczka E et al.    | 2013 | -0.91 (-1.35, -0.47) | 44, 1217 (234) | 44, 1408 (181) | 14.10 |
| Chen PC et al.       | 2013 | -1.09 (-1.65, -0.53) | 44, 237 (124) | 20, 36 (81) | 13.07 |
| El-Kholy MG et al.   | 2015 | -1.53 (-2.24, -0.82) | 20, 83 (19) | 20, 117 (25) | 11.76 |
| Overall (I-squared = 78.4%, p < 0.001) |     | -0.87 (-1.34, -0.40) | 256 | 175 | 100.00 |

**Figure 3.** Forest plot of studies examining blood SOD values of OSA and controls.

### 3.3. Meta-Analysis of Serum/Plasma SOD Concentrations

#### 3.3.1. Study Characteristics

Five studies with a total of 591 OSA patients (mean age 46 years, 71% males) and 261 controls (mean age 49 years, 65% males) were evaluated [14,31–34].

#### 3.3.2. Risk of Bias

The risk of bias was considered low in all studies (Table 2).

#### 3.3.3. Results of Individual Studies and Syntheses

The forest plot for serum/plasma SOD concentrations in OSA patients and controls in the five studies is reported in Figure 5. In all studies [14,31–34], OSA patients had lower serum/plasma SOD concentrations compared to controls (mean difference range, $-3.24$ to $-0.18$) and the difference was statistically significant in two [32,33]. Extreme heterogeneity between studies was observed ($I^2 = 98.0\%$, $p < 0.001$). Thus, random-effects models were used. Overall, pooled results showed that serum/plasma SOD values were non-significantly lower in patients with OSA (SMD $= -1.11$, 95% CI $-2.45$ to $+0.22$; $p = 0.10$). The effect size was not substantially altered (range between $-1.35$ and $-0.57$, Figure 6), both in direction and magnitude, after sequentially removing individual studies.
3.2.4. Publication Bias

Assessment of publication bias was not possible because of the relatively small number of studies.

3.2.5. Certainty of Evidence

The initial level of certainty for blood SOD SMD values was considered low because of the observational nature of the selected studies (rating 2, 🕳️⊕⊕⊝⊝). After considering the presence of a low risk of bias in seven out of eight studies (no rating change required), a generally extreme and unexplained heterogeneity (serious limitation, downgrade one level), lack of indirectness (no rating change required), the relatively low imprecision (relatively narrow confidence intervals without threshold crossing, upgrade one level), the relatively large effect size (SMD $\bar{X} = 0.87$, upgrade one level), and lack of assessment of publication bias (downgrade one level), the overall level of certainty was considered low (rating 2, 🕳️⊕⊕⊝⊝).

3.3. Meta-Analysis of Serum/Plasma SOD Concentrations

3.3.1. Study Characteristics

Five studies with a total of 591 OSA patients (mean age 46 years, 71% males) and 261 controls (mean age 49 years, 65% males) were evaluated [14,31–34].

3.3.2. Risk of Bias

The risk of bias was considered low in all studies (Table 2).

3.3.3. Results of Individual Studies and Syntheses

The forest plot for serum/plasma SOD concentrations in OSA patients and controls in the five studies is reported in Figure 5. In all studies [14,31–34], OSA patients had lower serum/plasma SOD concentrations compared to controls (mean difference range, $-3.24$ to $-0.18$) and the difference was statistically significant in two [32,33]. Extreme heterogeneity between studies was observed ($I^2 = 98.0\%, p < 0.001$). Thus, random-effects models were used. Overall, pooled results showed that serum/plasma SOD values were non-significantly lower in patients with OSA (SMD $\bar{X} = -1.11$, 95% CI $-2.45$ to $+0.22$; $p = 0.10$). The effect size was not substantially altered (range between $-1.35$ and $-0.57$, Figure 6), both in direction and magnitude, after sequentially removing individual studies.

3.3.4. Publication Bias

Assessment of publication bias was not possible because of the relatively small number of studies.

**Figure 4.** Sensitivity analysis of the association between blood SOD and OSA disease. The influence of individual studies on the overall standardized mean difference (SMD) is shown. The middle vertical axis indicates the overall SMD and the two vertical axes indicate the 95% confidence intervals (CI). Hollow circles represent the pooled SMD when the remaining study is omitted from the meta-analysis. Two ends of each broken line represent 95% CI.

**Figure 5.** Forest plot of studies examining serum/plasma SOD values of OSA and controls.
Figure 6. Sensitivity analysis of the association between serum/plasma SOD and OSA disease. The influence of individual studies on the overall standardized mean difference (SMD) is shown. The middle vertical axis indicates the overall SMD and the two vertical axes indicate the 95% confidence intervals (CI). Hollow circles represent the pooled SMD when the remaining study is omitted from the meta-analysis. Two ends of each broken line represent 95% CI.

3.3.5. Certainty of Evidence

The initial level of certainty for serum/plasma SOD SMD values was considered low because of the observational nature of the selected studies (rating 2, ⊕⊕⊖⊖). After considering the presence of a low risk of bias in all studies (no rating change required), a generally extreme and unexplained heterogeneity (serious limitation, downgrade one level), lack of indirectness (no rating change required), the relatively high imprecision (confidence intervals with threshold crossing, downgrade one level), the relatively large effect size (SMD = 1.11, upgrade one level), and lack of assessment of publication bias (downgrade one level), the overall level of certainty was considered very low (rating 0, ⊖⊖⊖⊖).

4. Discussion

The pro-oxidant state resulting from the recurring hypoxia and reoxygenation cycles appears to be involved in the association between OSA and cardiovascular diseases [35]. Whilst the relationship between oxidative stress and OSA has been extensively explored, controversial results have been reported [36,37]. Several studies investigated the concentrations of oxidant molecules in OSA patients, and their correlation with the severity of the disease [38,39]. A more limited number of studies have sought to elucidate the activity of key antioxidant enzymes, such as SOD and glutathione peroxidase [15,40,41]. SOD represents an important antioxidant mechanism in the detoxification of the superoxide anion, the most abundant ROS molecule [42]. Consequently, the measurement of the circulating concentrations of this enzyme might be useful to monitor the antioxidant defences in OSA patients and the effect of therapies [43].

Our systematic review and meta-analysis sought to address the potential of SOD to characterize the presence of oxidative stress in OSA by evaluating the presence and the effect size of differences in the concentrations of this enzyme between OSA patients and controls. In all studies, the concentrations of SOD in were lower in OSA than in non-OSA controls. When assessing specific biological matrices, the overall SMD value of whole blood SOD concentrations was statistically significant whereas the pooled SMD of serum/plasma was not.

The SOD enzyme is present in three isoforms in humans, with distinct subcellular localization, cytoplasmic, mitochondrial, and extracellular for SOD1, SOD2, and SOD3, re-
respectively. This different location is important for compartmentalized redox signalling [42]. Particularly, the significant reduction of SOD activity in whole blood could be the result of the high exposure of blood cells, particularly the erythrocytes, to oxidative stress [44]. A possible reason for the discrepancy in the results from studies on whole blood vs. those on serum/plasma is that the measured concentrations of SOD in the former may reflect the activity of all three isoforms while those in the latter may specifically reflect the activity of the extracellular SOD3 isoform.

Whilst extreme between-study heterogeneity was observed both in studies on whole blood and in those on serum/plasma in sensitivity analysis the SMD was not substantially altered when individual studies were in turn omitted. The observed heterogeneity could be explained by a number of unreported factors, including pre-analytical information and patient characteristics such as dietary patterns, medications, smoking status, and comorbidities that might influence the oxidative/antioxidative balance.

A recent meta-analysis of 10 studies reported lower SOD concentrations in OSA when compared with the non OSA-control [45]. However, differently from this study, we conducted separate analyses according to the different biological matrix investigated, plasma-serum vs. whole blood, and we observed significant differences in SOD between OSA and non-OSA groups in whole blood, but not in serum. Furthermore, our analyses were enriched by a comprehensive assessment of the certainty of evidence according to GRADE. Therefore, the two studies provide complementary information on this issue.

In addition to the high heterogeneity observed, this study has some other limitations mainly due to the relatively small number of studies included and the paucity of information available to assess the presence of publication bias and the relationship between the SMD and disease severity based on the AHI. This prevented the conduct of a meta-regression analysis to investigate associations between the study effect size, study design, and analytical characteristics. These issues are likely to have affected the overall level of certainty that was considered to be low. Furthermore, the number of studies included was limited to those written in English.

Despite these limitations, our study represents the first meta-analysis that evaluated the association between OSA and SOD, according to the different biological matrix used, thus providing a useful background for the design and the conduct of larger prospective studies.

5. Conclusions

In conclusion, we observed that OSA patients have significantly lower whole blood concentrations of the antioxidant enzyme SOD in when compared to non-OSA controls. This supports the proposition that OSA is characterized by an impaired antioxidant capacity and highlights the potential utility of assessing SOD concentration in the corpuscular biological matrix. Prospective studies are required to further confirm the validity of SOD assessment in OSA to monitor the progress of the disease and the effect of specific therapies.

Author Contributions: Conceptualization, M.C.P., P.P., and A.Z.; methodology, M.C.P., A.Z. and A.A.M.; formal analysis, A.A.M., A.Z. and G.P.; data curation and investigation, M.C.P. and E.Z.; writing—original draft preparation, M.C.P. and E.Z.; writing—review, and editing, M.C.P., A.A.M., A.G.F. and P.P.; visualization, A.Z. and A.G.F.; supervision, P.P. and C.C. funding acquisition, P.P. and C.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by grants from: Ministry of Education, Universities and Research (MIUR) “Programma Operativo Nazionale (PON) Ricerca e Innovazione 2014–2020”, Asse 1 “Capitale Umano,” Azione I.2 A.I.M., “Attrazione e mobilità dei ricercatori,” Linea 1 (Mobilità dei Ricercatori); University of Sassari, Fondo di Ateneo per la Ricerca: annualità 2019 e annualità 2020.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in review.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sforza, E.; Roche, F. Chronic intermittent hypoxia and obstructive sleep apnea: An experimental and clinical approach. *Hypoxia 2016*, 4, 99–108. [CrossRef] [PubMed]
2. Yamauchi, M.; Nakano, H.; Maekawa, J.; Okamoto, Y.; Ohnishi, Y.; Suzuki, T.; Kimura, H. Oxidative stress in obstructive sleep apnea. *Chest 2005*, 127, 1674–1679. [CrossRef]
3. Suzuki, Y.J.; Jain, V.; Park, A.M.; Day, R.M. Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. *Free Radic. Biol. Med. 2006*, 40, 1683–1692. [CrossRef]
4. Dorasamy, P. Obstructive sleep apnea and cardiovascular risk. *Ther. Clin. Risk Manag. 2007*, 3, 1105–1111. [PubMed]
5. Floras, J.S. Sleep Apnea and Cardiovascular Disease: An Enigmatic Risk Factor. *Circ. Res. 2018*, 122, 1741–1764. [CrossRef]
6. Lavie, L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia—Revisited—The bad ugly and good: Implications to the heart and brain. *Sleep Med. Rev. 2015*, 20, 27–45. [CrossRef] [PubMed]
7. Eisele, H.J.; Markert, P.; Schulz, R. Obstructive Sleep Apnea, Oxidative Stress, and Cardiovascular Disease: Evidence from Human Studies. *Oxidative Med. Cell. Longev. 2015*, 2015, 608438. [CrossRef]
8. Zorov, D.B.; Juhaszova, M.; Sollott, S.J. Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release. *Physiol. Rev. 2014*, 94, 909–950. [CrossRef]
9. Schieber, M.; Chandel, N.S. ROS Function in Redox Signaling and Oxidative Stress. *Curr. Biol. 2014*, 24, R453–R462. [CrossRef]
10. Wang, Y.; Branicky, R.; Noé, A.; Hekimi, S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. *J. Cell. Biol. 2018*, 217, 1915–1928. [CrossRef]
11. Fiedorczuk, P.; Stróżyński, A.; Olszewska, E. Is the Oxidative Stress in Obstructive Sleep Apnea Associated With Cardiovascular Complications?—Systematic Review. *J. Clin. Med. 2020*, 9, 3734. [CrossRef]
12. Wysocka, E.; Cofta, S.; Cymerys, M.; Gozdzik, J.; Torlinski, L.; Batura-Gabryel, H. The impact of the sleep apnea syndrome on oxidant-antioxidant balance in the blood of overweight and obese patients. *J. Physiol. Pharmac. 2008*, 59, 761–769.
13. Liu, W.; Fang, Y.; Luo, M.; Liu, K. Correlation of serum 8-hydroxydeoxyguanlyate level with disease severity and oxidative stress in osahs patients. *Acta Med. Mediterra. 2020*, 36, 3625.
14. Murri, M.; Garcia-Delgado, R.; Alcázar-Ramirez, J.; Linde, F.; Fernández-Ramos, A.; Cardona, F.; Tinhonhes, F.J. Assessment of cellular and plasma oxidative stress in SAHS patients before and after continuous positive airway pressure treatment. *Clin. Lab. 2010*, 56, 397–406. [PubMed]
15. Stanek, A.; Brożyna-Tkaczek, K.; Myśliński, W. Oxidative Stress Markers among Obstructive Sleep Apnea Patients. *Oxidative Med. Cell. Longev. 2021*, 2021, 1–8. [CrossRef] [PubMed]
16. Moola, S.; Munn, Z.; Tufanaru, C.; Aromataris, E.; Sears, K.; Sfetcu, R.; Currie, M.; Qureshi, R.; Mattis, P.; Lisy, K.; et al. Chapter 7: Systematic reviews of etiology and risk. In Joanna Briggs Institute Reviewer’s Manual for Evidence Synthesis; Aromataris, E., Munn, Z., Eds.; The Joanna Briggs Institute: Adelaide, Australia, 2020; Available online: https://reviewersmanual.joannabriggs.org/ (accessed on 31 October 2021).
17. Wang, Y.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol. 2014*, 14, 1–13. [CrossRef] [PubMed]
18. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med. Res. Methodol. 2005*, 5, 13. [CrossRef]
19. Bowden, J.; Tierney, J.F.; Copas, A.J.; Burdett, S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. *BMC Med. Res. Methodol. 2011*, 11, 41. [CrossRef]
20. Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med. 2002*, 21, 1539–1558. [CrossRef]
21. Tobias, A. Assessing the influence of a single study in the meta-analysis estimate. *Stata Tech. Bull. 1999*, 47, 15–17.
22. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for systematic reviews. *BMJ 2021*, 372, n71. [CrossRef] [PubMed]
23. A芰inha, M.A.; BaHamam, A.S.O. Lipid peroxides, superoxide dismutase and circulating IL-8 and GCP-2 in patients with severe obstructive sleep apnea: A pilot study. *Sleep Breath. 2005*, 9, 119–126. [CrossRef] [PubMed]
24. Cofta, S.; Wysocka, E.; Piorunek, T.; Rzymkowska, M.; Batura-Gabryel, H.; Torlinski, L. Oxidative stress markers in the blood of persons with different stages of obstructive sleep apnea syndrome. *J. Physiol. Pharm. 2008*, 59, 183–190.
25. Yagihara, F.; Lucchesi, L.M.; D’Almeida, V.; De Mello, M.T.; Tufik, S.; Bittencourt, L.R.A. Oxidative stress and quality of life in elderly patients with obstructive sleep apnea syndrome: Are there differences after six months of Continuous Positive Airway Pressure treatment? *Clinics 2012*, 67, 565–571. [CrossRef]
26. Ntalapascha, M.; Makris, D.; Kyparos, A.; Tsilioni, I.; Kostikas, K.; Gourgoulianis, K.; Kouretas, D.; Zakynthinos, E. Oxidative stress in patients with obstructive sleep apnea syndrome. *Sleep Breath. 2013*, 17, 549–555. [CrossRef]
27. Sales, L.V.; Bruin, V.M.; D’Almeida, V.; Pompeia, S.; Bueno, O.F.; Tufik, S.; Bittencourt, L. Cognition and biomarkers of oxidative stress in obstructive sleep apnea. *Clinics 2013*, 68, 449–455. [CrossRef]
28. Wysocka, E.; Cofta, S.; Piorunek, T.; Dziegielew ska-Gesiak, S.; Bryl, W.; Torlinski, L. Blood Antioxidant Status, Dysglycemia and Obstructive Sleep Apnea. *Adv. Exp. Med. Biol. 2012*, 756, 121–129.
29. Chen, P.-C.; Guo, C.-H.; Tseng, C.-J.; Wang, K.-C.; Liu, P.-J. Blood trace minerals concentrations and oxidative stress in patients with obstructive sleep apnea. *J. Nutr. Health Aging* 2013, 17, 639–644. [CrossRef]

30. El-Kholy, M.G.; El-Shafey, B.I.; Hantera, M.S.; Ganna, S.A.; El-Sorogy, H.A.; Faisl, A.E.-R.F. Effect of continuous positive airway pressure on oxidative stress accompanied by obstructive sleep apnea. *Egypt. J. Bronchol.* 2015, 9, 192–197. [CrossRef]

31. Lee, S.D.; Ju, G.; Choi, J.-A.; Kim, J.-W.; Yoon, I.-Y. The association of oxidative stress with central obesity in obstructive sleep apnea. *Sleep Breath.* 2011, 16, 511–517. [CrossRef] [PubMed]

32. Yildirim, T.; Alp, R. The role of oxidative stress in the relation between fibromyalgia and obstructive sleep apnea syndrome. *Eur. Rev. Med. Pharmacol. Sci.* 2017, 21, 20–29.

33. Zhou, L.; Ouyang, R.; Luo, H.; Peng, Y.; Chen, P.; Ren, S.; Liu, G. Dysfunction of Nrf2-ARE Signaling Pathway: Potential Pathogenesis in the Development of Neurocognitive Impairment in Patients with Moderate to Severe Obstructive Sleep Apnea-Hypopnea Syndrome. *Oxidative Med. Cell. Longev.* 2018, 2018, 1–15. [CrossRef]

34. Peres, B.U.; Allen, A.J.H.; Shah, A.; Fox, N.; Laher, I.; Almeida, F.; Jen, R.; Ayas, N. Obstructive Sleep Apnea and Circulating Biomarkers of Oxidative Stress: A Cross-Sectional Study. *Antioxidants* 2020, 9, 476. [CrossRef] [PubMed]

35. Jean-Louis, G.; Zizi, F.; Brown, D.; Ogedegbe, G.; Borger, J.; McFarlane, S. Obstructive sleep apnea and cardiovascular disease: Evidence and underlying mechanisms. *Minerva Pneumol.* 2009, 48, 277–293.

36. Schulz, R.; Mahmoudi, S.; Hattar, K.; Sibelius, U.; Olschewski, H.; Mayer, K.; Seeger, W.; Grimminger, F. Enhanced Release of Superoxide from Polymorphonuclear Neutrophils in Obstructive Sleep Apnea. Impact of continuous positive airway pressure therapy. *Am. J. Respir. Crit. Care Med.* 2000, 162, 566–570. [CrossRef]

37. Ozturk, L.; Mansour, B.; Yuksel, M.; Yalcin, A.S.; Celicoglu, F.; Gokhan, N. Lipid peroxidation and osmotic fragility of red blood cells in sleep-apnea patients. *Clin. Chim. Acta* 2003, 332, 83–88. [CrossRef]

38. Pau, M.C.; Zinellu, E.; Fois, S.S.; Piras, B.; Pintus, G.; Carru, C.; Mangoni, A.A.; Fois, A.G.; Zinellu, A.; Pirina, P. Circulating Malondialdehyde Concentrations in Obstructive Sleep Apnea (OSA): A Systematic Review and Meta-Analysis with Meta-Regression. *Antioxidants* 2021, 10, 1053. [CrossRef] [PubMed]

39. Jordan, W.; Cohrs, S.; Degner, D.; Meier, A.; Rodenbeck, A.; Mayer, G.; Pilz, J.; Rüther, E.; Kornhuber, J.; Bleich, S. Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. *J. Neural Transm.* 2006, 113, 239–254. [CrossRef]

40. Turan, H.; Demir, C. Investigation of Lipid Peroxidation and Antioxidant Enzyme Activity in Sleep Apnea Patients. *Nat. Sci. Discov.* 2016, 2, 36–40. [CrossRef]

41. Kolesnikova, L.I.; Madaeva, I.M.; Semenova, N.V.; Vlasov, B.Y.; Grebenkina, L.A.; Daren'skaya, M.A.; Dolgikh, M.I. Antioxidant potential of the blood in men with obstructive sleep breathing disorders. *Bull. Exp. Biol. Med.* 2013, 154, 731–733. [CrossRef] [PubMed]

42. Tukai, T.; Ushio-Fukai, M. Superoxide dismutases: Role in redox signalling, vascular function, and diseases. *Antioxid. Redox Signal.* 2011, 15, 1583–1606.

43. Seyedsadjadi, N.; Grant, R. The Potential Benefit of Monitoring Oxidative Stress and Inflammation in the Prevention of Non-Communicable Diseases (NCDs). *Antioxidants* 2020, 10, 15. [CrossRef]

44. Revin, V.V.; Gromova, N.V.; Revina, E.S.; Samonova, A.Y.; Tychkov, A.Y.; Bochkareva, S.S.; Moskovkin, A.A.; Kuzmenko, T.P. The Influence of Oxidative Stress and Natural Antioxidants on Morphometric Parameters of Red Blood Cells, the Hemoglobin Oxygen Binding Capacity, and the Activity of Antioxidant Enzymes. *BioMed Res. Int.* 2019, 2019, 2109269. [CrossRef] [PubMed]

45. Tian, Z.; Sun, H.; Kang, J.; Mu, Z.; Liang, J.; Li, M. Association between the circulating superoxide dismutase and obstructive sleep apnea: A meta-analysis. *Eur. Arch. Oto-Rhino-Laryngol.* 2021. [CrossRef] [PubMed]